Typical interventions for schizophrenia do not improve long-term outcomes, even when administered early, a new study reports. Read More
Advertisements
··5 min read
A new machine-learning algorithm that analyzes EEG data can identify reliable and robust neural signatures associated with antidepressant treatment response. Read More
A single dose of the psychedelic psilocybin reduces depression, anxiety, and feelings of hopelessness in cancer patients for 12 months after the drug is administered. Read More
During memory tasks, people with psychosis have different patterns of activity in the prefrontal and mediotemporal brain areas compared to those without the disorder. When exposed to cannabidiol (CBD), the activity of the brain areas became more like those seen in the controls for people with psychosis. Patients reported a decrease in symptoms of psychosis following one dose of CBD. Researchers stress that no definitive conclusions could be made about the effectiveness of CBD use over a sustained period. Read More
Numerous recent studies claim psychedelics, such as psilocybin, can help treat a range of mental health problems from depression to PTSD. Researchers investigate how psychedelics can help us become more "nature-connected" and increase a sense of environmental responsibility. Read More
Psychedelics, such as psilocybin, provide lasting improvements in mood and feelings of social connectedness, after the effect of the drug has worn off. Read More
Backing up previous research, a new study reveals psychedelics can have beneficial effects for treating PTSD when combined with traditional trauma-focused psychotherapy. Findings suggest MDMA assisted therapy is significantly more effective at treating patients with persistent PTSD than psychotherapy alone. Read More
Alteration of placental serotonin levels due to maternal depression or antidepressant use may be associated with the disruption of placental estrogen production. Read More
Younger people with bipolar disorder responded better to the antidepressant Latuda when they had increased inflammation biomarkers in their blood. Findings suggest C-reactive protein could be a predictive biomarker to identify which patients will respond to the antidepressant. Read More
Researchers have distinguished two different molecular pathways responsible for addiction and the prosocial feelings generated by MDMA. The findings could lead to novel treatments for psychiatric disorders marked by withdrawal and social awkwardness. Read More
A new study challenges existing theories about how benzodiazepines, such as valium, work to calm nerves. Researchers report a 'sticky' gene called Shisa7 plays a critical role in the regulation of inhibitory neural circuits, and the sedative effects benzodiazepines have on circuit activity. Read More
The proportion of those aged 65 and older prescribed antidepressants has more than doubled over two decades, from 4.2% in the 90s to 10.7% in twenty years later. However, the prevalence of depression among the age group has dropped since the 90s from 7.9% to 6.8%. Read More
